| ［1］ |
Sung H，Ferlay J，Siegel RL，et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries［J］. CA Cancer J Clin. 2021，71（3）:209-249.
|
| ［2］ |
Ghosh A，Gopinath SCB. Molecular Mechanism of Breast Cancer and Predisposition of Mouse Mammary Tumor Virus Propagation Cycle［J］. Curr Med Chem，2025，32（12）:2330-2348.
|
| ［3］ |
Li J，Wang D，Song S，et al. Analyzing the potential targets and mechanism of per- and polyfluoroalkyl substances（PFAS）on breast cancer by integrating network toxicology，single-cell sequencing，spatial transcriptomics，and molecular simulation［J］. Funct Integr Genomics，2025，25（1）:119.
|
| ［4］ |
Chen Z，Jia H，Zhang H，et al. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer？A study of 1363 patients［J］. Breast Cancer Res Treat，2023，202（2）:313-323.
|
| ［5］ |
Kumar N，Ehsan S，Banerjee S，et al. The unique risk factor profile of triple-negative breast cancer: a comprehensive meta-analysis［J］. J Natl Cancer Inst，2024，116（8）:1210-1219.
|
| ［6］ |
Nelson DR，Brown J，Morikawa A，et al. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics［J］. PLoS One，2022，17（2）:e0264637.
|
| ［7］ |
Ito A，Akama Y，Satoh-Takayama N，et al. Possible Metastatic Stage-Dependent ILC2 Activation Induces Differential Functions of MDSCs through IL-13/IL-13Rα1 Signaling during the Progression of Breast Cancer Lung Metastasis［J］. Cancers（Basel），2022，14（13）:3267.
|
| ［8］ |
杨娜，胡刚，潘越. 保乳术和改良根治术后行新辅助化疗对三阴性乳腺癌血清标志物影响［J/OL］. 中华普外科手术学杂志（电子版），2025，19（3）:345-348.
|
| ［9］ |
刘小娜，史博慧，马晓霞，等. 乳腺癌不同手术方式对术后并发症及康复影响的对比观察［J/OL］. 中华普外科手术学杂志（电子版），2025，19（5）:551-554.
|
| ［10］ |
Kim U，Chakrabarti R. MDSCs in Breast Cancer: Metastasis，Lipid Metabolism，and Therapeutics［J］. Mol Cancer Res，2025，23（12）:959-970.
|
| ［11］ |
Gjerstorff MF，Traynor S，Gammelgaard OL，et al. PDX Models: A Versatile Tool for Studying the Role of Myeloid-Derived Suppressor Cells in Breast Cancer［J］.Cancers（Basel），2022，14（24）:6153.
|
| ［12］ |
Liu C，Qiang J，Deng Q，et al. ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression［J］. Cancer Res，2021，81（23）:5919-5934.
|
| ［13］ |
Liu H，Wang Z，Zhou Y，et al. MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target［J］. Front Immunol，2023，14:1199273.
|
| ［14］ |
Liu W，Wu J，Zhang X，et al. PKM2 orchestrates tumor progression via metabolic reprogramming and MDSCs-mediated immune suppression in the tumor microenvironment［J］. Front Immunol，2025，16:1588019.
|
| ［15］ |
Abdollahzadeh B，Cantale Aeo NM，Giordano N，et al. The NF-κB1/p50 Subunit Influences the Notch/IL-6-Driven Expansion of Myeloid-Derived Suppressor Cells in Murine T-Cell Acute Lymphoblastic Leukemia［J］. Int J Mol Sci，2024，25（18）:9882-9896.
|
| ［16］ |
Wang Z，Jiang R，Li Q，et al. Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients［J］. J Clin Med，2021，10（8）:1768.
|
| ［17］ |
Veglia F，Sanseviero E，Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity［J］. Nat Rev Immunol，2021，21（8）:485-498.
|
| ［18］ |
Cui J，Wu D，Lv D. Predicting survival and immune status of breast cancer patients based on prognostic features related to PANoptosis［J］. Discov Oncol，2025，16（1）:527-543.
|
| ［19］ |
Chu Y，Yao Y，Hu Q，et al. Riskscore Model Based on Oxidative Stress-Related Genes May Facilitate the Prognosis Evaluation for Patients With Colon Cancer［J］. Clin Transl Gastroenterol，2023，14（6）:e00582.
|
| ［20］ |
Li Q，Chu Y，Yao Y，et al. A Treg-related riskscore model may improve the prognosis evaluation of colorectal cancer［J］. J Gene Med，2024，26（2）:e3668.
|
| ［21］ |
Cole K，Al-Kadhimi Z，Talmadge JE. Role of myeloid-derived suppressor cells in tumor recurrence［J］. Cancer Metastasis Rev，2023，42（1）:113-142.
|
| ［22］ |
Sun H，Tang C，Chung SH，et al. Blocking DCIR mitigates colitis and prevents colorectal tumors by enhancing the GM-CSF-STAT5 pathway［J］.Cell Rep，2022，40（5）:111158.
|
| ［23］ |
Jeong H，Koh J，Kim S，et al. Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer［J］. J Immunother Cancer，2025，13（3）:e010612.
|
| ［24］ |
Zhang K，Zakeri A，Alban T，et al. VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms［J］. Cell Rep，2024，43（1）:113661.
|
| ［25］ |
Zhao H，Teng D，Yang L，et al. Myeloid-derived itaconate suppresses cytotoxic CD8+ T cells and promotes tumour growth［J］. Nat Metab，2022，4（12）:1660-1673.
|
| ［26］ |
Zhao Z，Qin J，Qian Y，et al. FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion［J］. J Hematol Oncol，2024，17（1）:9.
|
| ［27］ |
Ajith A，Mamouni K，Horuzsko DD，et al. Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti-PD-1 resistance［J］. J Clin Invest，2023，133（21）:e167951.
|
| ［28］ |
Le H，Wang Y，Zhou J，et al. Git2 deficiency promotes MDSCs recruitment in intestine via NF-κB-CXCL1/CXCL12 pathway and ameliorates necrotizing enterocolitis［J］.Mucosal Immunol，2024，17（5）:1060-1071.
|
| ［29］ |
Wang D，Cheng C，Chen X，et al. IL-1β Is an Androgen-Responsive Target in Macrophages for Immunotherapy of Prostate Cancer［J］. Adv Sci（Weinh），2023，10（17）:e2206889.
|
| ［30］ |
Liao W，He C，Yang S，et al. Bioinformatics and experimental analyses of glutamate receptor and its targets genes in myocardial and cerebral ischemia［J］.BMC Genomics，2023，24（1）:300.
|